Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT02684240
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO)

Active Ingredients

Drugs in Phase 2 Trials (1)

nitazoxanide (Alinia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1